Alzheimer's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who agree to sign the electronic consent form
- Adults aged 45 years or older at the time of signing the consent form
- People who live in France
- People who can read and understand French, or who have a legal representative to help them do so
- People who are able to sign the consent form electronically
- People who are enrolled in the French national health insurance system
- People who have access to the internet and a valid email address
- People who are able to collect a saliva sample themselves using a provided kit and send it back
Who may not be able to join:
- People who do not sign the consent form
- People who are unable to read or understand French and do not have a legal representative to assist
- People younger than 45 years old at the time of signing the consent form
- People with a known significant memory or thinking condition, severe dementia, or a psychiatric condition that prevents them from giving informed consent
- People who have had a diagnosed problem with alcohol or drug dependence within the past 24 months
- People who cannot reliably be reached by email or phone
- People who have already taken part in the ALZEVIT study or its pilot phase
- People who are under a legal protection arrangement such as guardianship, curatorship, or judicial or administrative custody
- People whose physical condition means they are unable to carry out the tasks the study requires
- People whom the study investigator does not think will be able to follow the study procedures reliably
- People who work on this study as staff (such as investigators, coordinators, or assistants) or who are close family members of study staff
- People who are currently in prison or otherwise deprived of their liberty by a court or administrative decision
- People with any illness or condition that, in the investigator's judgement, would affect their safety or ability to participate
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Audrey GABELLE,, MD, PhD, CMRR Languedoc-Roussillon - Montpellier
Phone: +33 (0) 389 911 321
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
1. APOE genotype distribution in the study population; 2. Feasibility of large-scale decentralized APOE genotyping registry; 3. Identification of APOE ε4/ε4 homozygotes in the national cohort; 4. Establishment of a secure longitudinal APOE registry
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.